Effects of Selenium and Melatonin on Ocular Ischemic Syndrome

Biomed Res Int. 2019 Dec 6:2019:8080564. doi: 10.1155/2019/8080564. eCollection 2019.

Abstract

Purpose: To determine the effects of selenium, melatonin, and selenium + melatonin administered for one month on anterior chamber (AC) malondialdehyde (MDA) and AC glutathione (GSH) levels in patients with ocular ischemic syndrome.

Materials and methods: Thirty-five patients were included in the study. Study groups were formed as follows: (1) control group, (2) ischemia group, (3) selenium + ischemia group, (4) melatonin + ischemia group, and (5) selenium + melatonin + ischemia group. AC samples were obtained. MDA and GSH levels in AC samples were evaluated.

Results: MDA levels were significantly increased in ischemia groups. Selenium and melatonin supplementation resulted in reduction of MDA levels and significant increase in GSH values.

Discussion: Increased lipid peroxidation associated with ischemia of the anterior segment has been prevented by selenium and melatonin supplementation. This trial is registered with ClinicalTrials.gov NCT04005222.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Eye / blood supply*
  • Eye / pathology
  • Female
  • Glutathione / metabolism
  • Humans
  • Ischemia / drug therapy*
  • Male
  • Malondialdehyde
  • Melatonin / pharmacology
  • Melatonin / therapeutic use*
  • Middle Aged
  • Selenium / pharmacology
  • Selenium / therapeutic use*
  • Syndrome

Substances

  • Malondialdehyde
  • Glutathione
  • Selenium
  • Melatonin

Associated data

  • ClinicalTrials.gov/NCT04005222